Search results for "From ACP InternistWeekly"


 
Results 31 - 36 of about 36 for "From ACP InternistWeekly".
Sort by: Relevance | Newest | Oldest

Diabetes risk from statins may be offset by reduction in cardiovascular events

Atorvastatin, 80 mg/d, carries a higher risk of developing diabetes than do lower doses, but only among patients who already have multiple risk factors, a study found.
https://diabetes.acponline.org/archives/2013/01/11/6.htm
11 Jan 2013

Standard blood glucose targets are lower than HbA1c goals require

A recent study determined the pre- and postprandial blood glucose levels that should be targeted to reach a specific HbA1c goal in patients with type 1 or type 2 diabetes.
https://diabetes.acponline.org/archives/2014/03/14/5.htm
14 Mar 2014

Clopidogrel associated with decreased benefit in diabetics post-MI

Diabetics benefit less from receiving clopidogrel after myocardial infarction than non-diabetics, a study found.
https://diabetes.acponline.org/archives/2012/09/14/7.htm
14 Sep 2012

EHRs may improve diabetes management and achievement of treatment goals, particularly among those with worst disease control

Use of a commercially available electronic health record (EHR) was associated with improved care processes and better achievement of intermediate treatment outcomes for outpatients with diabetes, a study found.
https://diabetes.acponline.org/archives/2012/10/12/5.htm
12 Oct 2012

Bariatric surgery leads to short-term improved glycemic control and weight loss in moderately obese diabetics

Bariatric surgery in diabetic patients with a body mass index of 30 to 35 kg/m2 is associated with more short-term weight loss and better intermediate outcomes than nonsurgical treatments, but data on long-term effects are limited, a review found.
https://diabetes.acponline.org/archives/2013/06/14/6.htm
14 Jun 2013

Linagliptin non-inferior to glimepiride in two-year trial

Linagliptin was non-inferior to glimepiride in lowering hemoglobin A1c in type 2 diabetes patients, according to a study designed, conducted and analyzed by linagliptin's manufacturer, Boehringer Ingelheim.
https://diabetes.acponline.org/archives/2012/07/13/6.htm
13 Jul 2012

Result Page: Prev   1   2   3   4   Next